<p><em>- 添加 dordaviprone 强化了 Jazz 的晚期肿瘤学管线，并重申了对解决具有重大未满足需求的罕见疾病的承诺 -</em></p>
<p>, /PRNewswire/ -- Jazz Pharmaceuticals plc (纳斯达克: JAZZ)（&#34;Jazz&#34; 或 &#34;公司&#34;）今天宣布成功完成对 Chimerix, Inc.（&#34;Chimerix&#34;）的收购，交易金额约为 9.35 亿美元现金。Chimerix 现在是 Jazz 的全资子公司。</p>
<p>&#34;将 Chimerix 纳入 Jazz 为我们的肿瘤学产品组合增添了一种新型药物，并推动我们解决未满足患者需求的努力，&#34; Jazz 的董事长兼首席执行官 Bruce Cozadd 说。&#34;Dordaviprone 有潜力成为 FDA 首个也是唯一批准用于 H3 K27M 突变弥漫性胶质瘤患者的治疗，如果获得批准，将提供一个有前景的短期商业机会。我们很高兴欢迎 Chimerix 的优秀团队，共同推进 dordaviprone，利用我们的开发和商业能力，尽快将这一疗法提供给患者，预计在今年下半年。&#34;</p>
<p>dordaviprone 的加入是一种新型的首创小分子治疗，正在开发用于 H3 K27M 突变弥漫性胶质瘤，进一步丰富并为 Jazz 的肿瘤学管线增加了短期商业机会。dordaviprone 目前正在接受美国食品药品监督管理局（FDA）的优先审查，处方药用户收费法案（PDUFA）行动日期定于 2025 年 8 月 18 日。如果在美国获得批准，该疗法可能有资格获得罕见儿科疾病优先审查凭证（PRV）。dordaviprone 还在进行中的 III 期 ACTION 试验中进行研究，以评估其在新诊断的非复发性 H3 K27M 突变弥漫性胶质瘤患者放疗后的使用，可能将其应用扩展到一线治疗。</p>
<p><strong>交易详情</strong> Jazz 对 Chimerix 所有流通普通股（每股面值 0.001 美元）的要约于 2025 年 4 月 17 日东部时间晚上 11:59 之后的一分钟到期。Jazz 已接受有效投标且未有效撤回的所有股票，现金支付每股 8.55 美元，不计利息，并可能因适用的预扣税而减少。在接受投标股票后，Jazz 通过与 Chimerix 合并的方式完成了对 Chimerix 的收购，合并方为 Pinetree Acquisition Sub, Inc.，一家特拉华州公司，是 Jazz 的间接全资子公司（&#34;购买方&#34;）。合并后，购买方的独立存在终止，Chimerix 继续作为存续公司，并成为 Jazz 的间接全资子公司。有关要约的更多详细信息，请参阅 Jazz 今天向 SEC 提交的 8-K 表格。</p>
<p><strong>关于 Dordaviprone</strong> Dordaviprone (ONC201) 是一种新型的首创小分子 imipridone，选择性靶向线粒体蛋白酶 ClpP 和多巴胺受体 D2 (DRD2)。Dordaviprone 的独特作用机制包括对关键表观遗传修饰的改变，如 H3 K27me3 丧失的逆转，这是 H3 K27M 突变胶质瘤的标志。</p>
<p><strong>关于 Jazz Pharmaceuticals</strong> Jazz Pharmaceuticals plc (NASDAQ: JAZZ) 是一家全球生物制药公司，其宗旨是创新以改变患者及其家庭的生活。我们致力于为患有严重疾病的人开发改变生活的药物——通常是治疗选择有限或没有治疗选择的疾病。我们拥有多样化的上市药物组合，包括领先的睡眠障碍和癫痫治疗药物，以及不断增长的癌症治疗组合。我们以患者为中心、以科学为驱动的方法推动我们在肿瘤学和神经科学领域的创新治疗的研究和开发进展。Jazz 总部位于爱尔兰都柏林，在多个国家设有研究和开发实验室、制造设施及员工，致力于为全球患者服务。有关更多信息，请访问 www.jazzpharmaceuticals.com。</p>
<p><strong>关于前瞻性声明的警示</strong> 本通讯包含涉及 Jazz 和 Chimerix 未来事件及未来表现的前瞻性声明，这些声明涉及风险和不确定性，包括关于收购的潜在好处的声明，包括 dordaviprone 有可能成为 FDA 批准的首个也是唯一的 H3 K27M 突变弥漫性胶质瘤患者治疗药物的潜力，以及其可能提供的有希望的近期商业机会；如果获得批准，dordaviprone 在美国的近期商业推出潜力；正在进行的第三阶段 ACTION 试验确认 dordaviprone 在复发性 H3 K27M 突变弥漫性胶质瘤中的临床益处并扩展其在一线患者中的使用潜力；dordaviprone 可能有资格获得罕见儿科疾病 PRV；以及其他非历史事实的声明。实际结果可能与这些前瞻性声明中预期的结果有实质性差异。可能导致这些前瞻性声明不准确的风险包括但不限于：预测监管批准或行动的时间或结果的困难的不确定性；与实现收购预期好处相关的风险，包括收购预期好处未能实现或未能在预期时间内实现的可能性，以及 Jazz 和 Chimerix 未能成功整合或整合可能比预期更困难、耗时或成本更高；交易对员工、客户、供应商、其他商业伙伴或政府实体关系的影响；显著的交易成本；未知或无法估计的负债；与收购相关的诉讼和/或监管行动的风险；有效推出和商业化产品及产品候选者（如 dordaviprone，如果获得批准）；成功完成与 dordaviprone 相关的开发和监管活动；获得和维持 Jazz 产品的足够覆盖和报销；耗时且不确定的监管批准过程，包括 Chimerix 针对 dordaviprone 寻求加速批准用于治疗 H3 K27M 突变弥漫性胶质瘤的成人和儿童患者的 NDA 可能未能及时获得 FDA 批准或根本未获批准的风险，以及 Chimerix 和/或 Jazz 可能未能在 dordaviprone 潜在批准时获得罕见儿科疾病 PRV；药品开发的高成本和耗时以及临床成功的不确定性，包括与成功启动或完成临床试验和评估患者相关的失败或延迟风险，包括当前和计划中的 dordaviprone 未来临床试验；全球经济、金融和医疗系统的干扰，以及当前和未来可能对 Jazz 的业务运营和财务结果产生负面影响的潜在影响；以及影响 Jazz 的其他风险和不确定性，包括在其向美国证券交易委员会的文件和报告中不时描述的 “风险因素” 标题下的风险，包括 Jazz 截至 2024 年 12 月 31 日的财政年度的 10-K 年度报告及未来的文件和报告。公司目前未意识到的其他风险和不确定性也可能影响其前瞻性声明，并可能导致实际结果和事件时间与预期有实质性差异。本新闻稿中所作的前瞻性声明仅在本日期作出，即使公司随后在其网站或其他地方提供这些声明。公司没有义务更新或补充任何前瞻性声明，以反映实际结果、新信息、未来事件、预期变化或在前瞻性声明作出日期之后存在的其他情况。</p>
<p><strong>联系方式</strong></p>
<p><strong>投资者：</strong> Jeff Macdonald</p>
<p>投资者关系执行董事</p>
<p>Jazz Pharmaceuticals plc</p>
<p>[email protected]</p>
<p>爱尔兰 +353 1 634 3211</p>
<p>美国 +1 650 496 2717</p>
<p><strong>媒体：</strong></p>
<p>Kristin Bhavnani</p>
<p>全球企业传播负责人</p>
<p>Jazz Pharmaceuticals plc</p>
<p>[email protected]</p>
<p>爱尔兰 +353 1 637 2141</p>
<p>美国 +1 215 867 4948</p>
<p>来源 Jazz Pharmaceuticals plc</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNDIxJk5ld3NJdGVtSWQ9U0Y2ODMwNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA0MjExNjA1UFJfTkVXU19VU1BSX19fX19TRjY4MzA0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNDIxJk5ld3NJdGVtSWQ9U0Y2ODMwNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA0MjExNjA1UFJfTkVXU19VU1BSX19fX19TRjY4MzA0"/></p>

爵士制药

CMRX

<p>爵士制药已完成对 Chimerix 的收购，交易金额约为 9.35 亿美元现金。这项收购增强了爵士的肿瘤学管线，特别是 dordaviprone，这是一种潜在的首个获得 FDA 批准的 H3 K27M 突变弥漫性胶质瘤治疗药物。该药物正在接受 FDA 的优先审查，预计将在 2025 年 8 月 18 日之前作出决定。此次合并使 Chimerix 成为爵士的全资子公司，爵士旨在利用其能力尽快将该疗法提供给患者。爵士致力于开发针对严重疾病的创新治疗方案</p>

<p><em>- Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need -</em></p>
<div class="lb-trans"><p><em>- 添加 dordaviprone 强化了 Jazz 的晚期肿瘤学管线，并重申了对解决具有重大未满足需求的罕见疾病的承诺 -</em></p>
</div><p>, /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (&#34;Jazz&#34; or the &#34;Company&#34;) today announced the successful completion of its acquisition of Chimerix, Inc. (&#34;Chimerix&#34;) for approximately $935 million in cash. Chimerix is now a wholly owned subsidiary of Jazz.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Jazz Pharmaceuticals plc (纳斯达克: JAZZ)（&#34;Jazz&#34; 或 &#34;公司&#34;）今天宣布成功完成对 Chimerix, Inc.（&#34;Chimerix&#34;）的收购，交易金额约为 9.35 亿美元现金。Chimerix 现在是 Jazz 的全资子公司。</p>
</div><p>&#34;Bringing Chimerix into Jazz adds a novel medicine to our oncology portfolio and advances our efforts to address unmet patient needs,&#34; said Bruce Cozadd, chairman and chief executive officer of Jazz. &#34;Dordaviprone has the potential to become the first and only FDA-approved therapy for patients with H3 K27M-mutant diffuse glioma and offers a promising near-term commercial opportunity, if approved. We are excited to welcome Chimerix's talented team as we collectively continue to advance dordaviprone, leveraging our development and commercial capabilities to deliver this therapy to patients as soon as the second half of this year.&#34;</p>
<div class="lb-trans"><p>&#34;将 Chimerix 纳入 Jazz 为我们的肿瘤学产品组合增添了一种新型药物，并推动我们解决未满足患者需求的努力，&#34; Jazz 的董事长兼首席执行官 Bruce Cozadd 说。&#34;Dordaviprone 有潜力成为 FDA 首个也是唯一批准用于 H3 K27M 突变弥漫性胶质瘤患者的治疗，如果获得批准，将提供一个有前景的短期商业机会。我们很高兴欢迎 Chimerix 的优秀团队，共同推进 dordaviprone，利用我们的开发和商业能力，尽快将这一疗法提供给患者，预计在今年下半年。&#34;</p>
</div><p>The addition of dordaviprone, a novel first-in-class small molecule treatment in development for H3 K27M-mutant diffuse glioma, further diversifies and adds near-term commercial opportunity to Jazz's oncology pipeline. Dordaviprone is currently under Priority Review by the U.S. Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) action date set for August 18, 2025. If approved in the U.S., the therapy may be eligible for a Rare Pediatric Disease Priority Review Voucher (PRV). Dordaviprone is also being studied in the ongoing Phase 3 ACTION trial to evaluate its use in newly diagnosed, non-recurrent H3 K27M-mutant diffuse glioma patients following radiation treatment, potentially extending its use into the first-line setting.</p>
<div class="lb-trans"><p>dordaviprone 的加入是一种新型的首创小分子治疗，正在开发用于 H3 K27M 突变弥漫性胶质瘤，进一步丰富并为 Jazz 的肿瘤学管线增加了短期商业机会。dordaviprone 目前正在接受美国食品药品监督管理局（FDA）的优先审查，处方药用户收费法案（PDUFA）行动日期定于 2025 年 8 月 18 日。如果在美国获得批准，该疗法可能有资格获得罕见儿科疾病优先审查凭证（PRV）。dordaviprone 还在进行中的 III 期 ACTION 试验中进行研究，以评估其在新诊断的非复发性 H3 K27M 突变弥漫性胶质瘤患者放疗后的使用，可能将其应用扩展到一线治疗。</p>
</div><p><strong>Transaction Details</strong> Jazz's tender offer for all outstanding shares of common stock, par value $0.001 per share, of Chimerix expired at one minute after 11:59 p.m., Eastern Time, on April 17, 2025. Jazz has accepted for payment of $8.55 per share, in cash, without interest and subject to reduction for any applicable withholding taxes, all shares that were validly tendered and not validly withdrawn. Following its acceptance of the tendered shares, Jazz completed the acquisition of Chimerix through the merger of Pinetree Acquisition Sub, Inc., a Delaware corporation, an indirect wholly owned subsidiary of Jazz (&#34;Purchaser&#34;) with and into Chimerix (the &#34;Merger&#34;). As a result of the Merger, the separate existence of Purchaser ceased, and Chimerix continued as the surviving corporation and an indirect wholly owned subsidiary of Jazz. Additional details regarding the tender can be found in a form 8-K filed by Jazz today with the SEC.</p>
<div class="lb-trans"><p><strong>交易详情</strong> Jazz 对 Chimerix 所有流通普通股（每股面值 0.001 美元）的要约于 2025 年 4 月 17 日东部时间晚上 11:59 之后的一分钟到期。Jazz 已接受有效投标且未有效撤回的所有股票，现金支付每股 8.55 美元，不计利息，并可能因适用的预扣税而减少。在接受投标股票后，Jazz 通过与 Chimerix 合并的方式完成了对 Chimerix 的收购，合并方为 Pinetree Acquisition Sub, Inc.，一家特拉华州公司，是 Jazz 的间接全资子公司（&#34;购买方&#34;）。合并后，购买方的独立存在终止，Chimerix 继续作为存续公司，并成为 Jazz 的间接全资子公司。有关要约的更多详细信息，请参阅 Jazz 今天向 SEC 提交的 8-K 表格。</p>
</div><p><strong>About Dordaviprone</strong> Dordaviprone (ONC201) is a novel first-in-class small molecule imipridone that selectively targets the mitochondrial protease ClpP and dopamine receptor D2 (DRD2). Dordaviprone's unique mechanism of action includes alterations of key epigenetic modifications such as reversal of H3 K27me3-loss, which is the hallmark of H3 K27M-mutant gliomas.</p>
<div class="lb-trans"><p><strong>关于 Dordaviprone</strong> Dordaviprone (ONC201) 是一种新型的首创小分子 imipridone，选择性靶向线粒体蛋白酶 ClpP 和多巴胺受体 D2 (DRD2)。Dordaviprone 的独特作用机制包括对关键表观遗传修饰的改变，如 H3 K27me3 丧失的逆转，这是 H3 K27M 突变胶质瘤的标志。</p>
</div><p><strong>About Jazz Pharmaceuticals</strong> Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.</p>
<div class="lb-trans"><p><strong>关于 Jazz Pharmaceuticals</strong> Jazz Pharmaceuticals plc (NASDAQ: JAZZ) 是一家全球生物制药公司，其宗旨是创新以改变患者及其家庭的生活。我们致力于为患有严重疾病的人开发改变生活的药物——通常是治疗选择有限或没有治疗选择的疾病。我们拥有多样化的上市药物组合，包括领先的睡眠障碍和癫痫治疗药物，以及不断增长的癌症治疗组合。我们以患者为中心、以科学为驱动的方法推动我们在肿瘤学和神经科学领域的创新治疗的研究和开发进展。Jazz 总部位于爱尔兰都柏林，在多个国家设有研究和开发实验室、制造设施及员工，致力于为全球患者服务。有关更多信息，请访问 www.jazzpharmaceuticals.com。</p>
</div><p><strong>Caution Concerning Forward-Looking Statements</strong> This communication contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Jazz and Chimerix, including statements regarding the prospective benefits of the acquisition, including benefits from dordaviprone's potential to become the first and only FDA-approved therapy for patients with H3 K27M-mutant diffuse glioma and its potential to offer a promising near-term commercial opportunity; the potential for a near-term commercial launch of dordaviprone in the U.S. if approved; the potential of the ongoing Phase 3 ACTION trial to confirm clinical benefit of dordaviprone in recurrent H3 K27M-mutant diffuse glioma and extend its use in first-line patients; dordaviprone potentially being eligible for a Rare Pediatric Disease PRV; and other statements that are not historical facts. Actual results could differ materially from those anticipated in these forward-looking statements. Risks that may cause these forward-looking statements to be inaccurate include, without limitation: uncertainties as to the difficulty of predicting the timing or outcome of regulatory approvals or actions, if any; risks related to the ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period and that Jazz and Chimerix will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; the effects of the transaction on relationships with employees, customers, suppliers, other business partners or governmental entities; significant transaction costs; unknown or inestimable liabilities; the risk of litigation and/or regulatory actions related to the acquisition; effectively launching and commercializing products and product candidates such as dordaviprone, if approved; the successful completion of development and regulatory activities with respect to dordaviprone; obtaining and maintaining adequate coverage and reimbursement for Jazz's products; the time-consuming and uncertain regulatory approval process, including the risk that Chimerix's NDA for dordaviprone seeking accelerated approval for treatment of H3 K27M-mutant diffuse glioma in adult and pediatric patients with progressive disease following prior therapy may not be approved by FDA in a timely manner or at all, and that Chimerix and/or Jazz may not receive a Rare Pediatric Disease PRV upon potential approval of dordaviprone; the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients, including with respect to current and planned future clinical trials of dordaviprone; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to Jazz's business operations and financial results; and other risks and uncertainties affecting Jazz, including those described from time to time under the caption &#34;Risk Factors&#34; and elsewhere in its filings and reports with the U.S. Securities and Exchange Commission, including Jazz's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and future filings and reports. Other risks and uncertainties of which the Company is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this press release are made only as of the date hereof, even if they are subsequently made available by the Company on its website or otherwise. The Company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.</p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示</strong> 本通讯包含涉及 Jazz 和 Chimerix 未来事件及未来表现的前瞻性声明，这些声明涉及风险和不确定性，包括关于收购的潜在好处的声明，包括 dordaviprone 有可能成为 FDA 批准的首个也是唯一的 H3 K27M 突变弥漫性胶质瘤患者治疗药物的潜力，以及其可能提供的有希望的近期商业机会；如果获得批准，dordaviprone 在美国的近期商业推出潜力；正在进行的第三阶段 ACTION 试验确认 dordaviprone 在复发性 H3 K27M 突变弥漫性胶质瘤中的临床益处并扩展其在一线患者中的使用潜力；dordaviprone 可能有资格获得罕见儿科疾病 PRV；以及其他非历史事实的声明。实际结果可能与这些前瞻性声明中预期的结果有实质性差异。可能导致这些前瞻性声明不准确的风险包括但不限于：预测监管批准或行动的时间或结果的困难的不确定性；与实现收购预期好处相关的风险，包括收购预期好处未能实现或未能在预期时间内实现的可能性，以及 Jazz 和 Chimerix 未能成功整合或整合可能比预期更困难、耗时或成本更高；交易对员工、客户、供应商、其他商业伙伴或政府实体关系的影响；显著的交易成本；未知或无法估计的负债；与收购相关的诉讼和/或监管行动的风险；有效推出和商业化产品及产品候选者（如 dordaviprone，如果获得批准）；成功完成与 dordaviprone 相关的开发和监管活动；获得和维持 Jazz 产品的足够覆盖和报销；耗时且不确定的监管批准过程，包括 Chimerix 针对 dordaviprone 寻求加速批准用于治疗 H3 K27M 突变弥漫性胶质瘤的成人和儿童患者的 NDA 可能未能及时获得 FDA 批准或根本未获批准的风险，以及 Chimerix 和/或 Jazz 可能未能在 dordaviprone 潜在批准时获得罕见儿科疾病 PRV；药品开发的高成本和耗时以及临床成功的不确定性，包括与成功启动或完成临床试验和评估患者相关的失败或延迟风险，包括当前和计划中的 dordaviprone 未来临床试验；全球经济、金融和医疗系统的干扰，以及当前和未来可能对 Jazz 的业务运营和财务结果产生负面影响的潜在影响；以及影响 Jazz 的其他风险和不确定性，包括在其向美国证券交易委员会的文件和报告中不时描述的 “风险因素” 标题下的风险，包括 Jazz 截至 2024 年 12 月 31 日的财政年度的 10-K 年度报告及未来的文件和报告。公司目前未意识到的其他风险和不确定性也可能影响其前瞻性声明，并可能导致实际结果和事件时间与预期有实质性差异。本新闻稿中所作的前瞻性声明仅在本日期作出，即使公司随后在其网站或其他地方提供这些声明。公司没有义务更新或补充任何前瞻性声明，以反映实际结果、新信息、未来事件、预期变化或在前瞻性声明作出日期之后存在的其他情况。</p>
</div><p><strong>Contacts</strong></p>
<div class="lb-trans"><p><strong>联系方式</strong></p>
</div><p><strong>Investors:</strong> Jeff Macdonald</p>
<div class="lb-trans"><p><strong>投资者：</strong> Jeff Macdonald</p>
</div><p>Executive Director, Investor Relations</p>
<div class="lb-trans"><p>投资者关系执行董事</p>
</div><p>Jazz Pharmaceuticals plc</p>
<div class="lb-trans"><p>Jazz Pharmaceuticals plc</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>Ireland +353 1 634 3211</p>
<div class="lb-trans"><p>爱尔兰 +353 1 634 3211</p>
</div><p>U.S. +1 650 496 2717</p>
<div class="lb-trans"><p>美国 +1 650 496 2717</p>
</div><p><strong>Media:</strong></p>
<div class="lb-trans"><p><strong>媒体：</strong></p>
</div><p>Kristin Bhavnani</p>
<div class="lb-trans"><p>Kristin Bhavnani</p>
</div><p>Head of Global Corporate Communications</p>
<div class="lb-trans"><p>全球企业传播负责人</p>
</div><p>Jazz Pharmaceuticals plc</p>
<div class="lb-trans"><p>Jazz Pharmaceuticals plc</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>Ireland +353 1 637 2141</p>
<div class="lb-trans"><p>爱尔兰 +353 1 637 2141</p>
</div><p>U.S. +1 215 867 4948</p>
<div class="lb-trans"><p>美国 +1 215 867 4948</p>
</div><p>SOURCE Jazz Pharmaceuticals plc</p>
<div class="lb-trans"><p>来源 Jazz Pharmaceuticals plc</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNDIxJk5ld3NJdGVtSWQ9U0Y2ODMwNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA0MjExNjA1UFJfTkVXU19VU1BSX19fX19TRjY4MzA0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=SF68304&amp;Transmission_Id=202504211605PR_NEWS_USPR_____SF68304&amp;DateId=20250421"/></p>

爵士制药完成对 Chimerix 的收购